Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded down 8.5% during trading on Monday . The stock traded as low as GBX 4.40 and last traded at GBX 4.40. 1,523,292 shares traded hands during mid-day trading, a decline of 47% from the average session volume of 2,874,877 shares. The stock had previously closed at GBX 4.81.
ImmuPharma Trading Down 2.0%
The firm’s fifty day moving average price is GBX 4.47 and its 200 day moving average price is GBX 5.79. The stock has a market capitalization of £28.14 million, a price-to-earnings ratio of -12.19 and a beta of 3.00.
ImmuPharma (LON:IMM – Get Free Report) last issued its quarterly earnings data on Wednesday, May 27th. The company reported GBX (0.37) EPS for the quarter. ImmuPharma had a negative return on equity of 1,397.44% and a net margin of 3,519.56%. On average, analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
